ViaCyte Revenue and Competitors
Estimated Revenue & Valuation
- ViaCyte's estimated annual revenue is currently $22.5M per year.
- ViaCyte received $80.0M in venture funding in November 2018.
- ViaCyte's estimated revenue per employee is $155,000
- ViaCyte's total funding is $289.5M.
Employee Data
- ViaCyte has 145 Employees.
- ViaCyte grew their employee count by 24% last year.
ViaCyte Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $202.6M | 1397 | N/A | N/A | N/A |
#2 | $3.1M | 20 | 18% | N/A | N/A |
What Is ViaCyte?
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte has two products in clinical development. The first is called the PEC-Direct product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01 cells) in a non-immunoprotective device. The PEC-Direct product candidate is being developed for type 1 diabetes (T1D) patients who have hypoglycemia unawareness, recurrent severe hypoglycemic episodes, and/or extreme glycemic lability. The second product is called the PEC-Encap (also known as VC-01) product candidate. The PEC-Encap product candidate delivers pancreatic progenitor cells in an immunoprotective device and is being developed as a potential therapy for all diabetes patients who use insulin to control their disease. www.viacyte.com
keywords:Biotechnology,Healthcare,Pharmaceuticals
$289.5M
Total Funding
145
Number of Employees
$22.5M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ViaCyte News
San Diego-based ViaCyte, a company which is using stem cell technology to develop treatments for Type 1 Diabetes, says it has raised $45M in an extension of its Series D funding round. The funding brings its Series D funding to more than $115M. The funding came from existing investors Bain Capit ...
ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding. The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Cap ...
ViaCyte, a clinical stage biotech company, has raised $115 million in Series D financing, to bring forward two phase 2 studies of type 1 diabetes candidates. Michael Yang, President and CEO, ViaCyte The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital ...
The only group to have reached the clinic with a similar approach, Viacyte, has had extremely mixed results (Regenerating insulin-producing ...
Global Pancreatic Beta-Cell Protection Market Analysis, Growth, Demand, Study & Forecast-2019-2025: ViaCyte, PharmaCyte Biotech, ...
Company profile section of players such as ViaCyte, PharmaCyte Biotech, Boehringer Ingelheim, GalaxoSmithKline, Beta-Cell NV, Novartis, ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 145 | 32% | $321M |
#2 | $42.1M | 145 | -7% | $26M |
#3 | $32.7M | 145 | 2% | $105M |
#4 | $23.9M | 145 | N/A | N/A |
#5 | $39.9M | 145 | -17% | N/A |
ViaCyte Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2001-10-04 | $7.0M | B | Article | |
| 2001-12-19 | $4.0M | Strategic Investmen | SurModics | Article |
| 2003-05-05 | $Undisclosed | D | Multiple | Article |
| 2007-07-17 | $25.0M | C | Johnson and Johnson Developmen | Article |
| 2013-07-11 | $10.6M | Undisclosed | Article | |
| 2014-02-07 | $7.0M | Undisclosed | JDRF | Article |
| 2014-08-11 | $5.4M | C-1 | Article | |
| 2014-08-26 | $20.0M | Undisclosed | Janssen Research & Development LLC | Article |
| 2017-05-23 | $10.0M | Undisclosed | Asset Management Partners, | Article |
| 2018-11-30 | $80.0M | D | Bain Capital Life Sciences | Article |
